BrightGene Bio Medical Technology C (688166) — Strategic Asset Allocation Index
BrightGene Bio Medical Technology C (688166) has a Strategic Asset Allocation Index of 97.1% as of June 2023. Strategic assets (PP&E of CN¥2.29 Billion plus long-term investments of CN¥-) total CN¥2.29 Billion, measured against net assets of CN¥2.35 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See BrightGene Bio Medical Technology C balance sheet quality to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
BrightGene Bio Medical Technology C Strategic Asset Allocation Index (2016–2022)
This chart shows how BrightGene Bio Medical Technology C's Strategic Asset Allocation Index has evolved across 7 annual periods from 2016 to 2022. As of June 2023, the index stands at 97.1%, representing strategic assets of CN¥2.29 Billion against net assets of CN¥2.35 Billion CNY. For live market cap and overall valuation, see BrightGene Bio Medical Technology C market capitalisation.
Annual Strategic Asset Allocation Index for BrightGene Bio Medical Technology C (2016–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for BrightGene Bio Medical Technology C from 2016 to 2022, covering 7 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See BrightGene Bio Medical Technology C (688166) net assets for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 92.6% | CN¥2.08 Billion | CN¥2.08 Billion | CN¥- | CN¥2.24 Billion | ▲ +13.5 pp |
| 2021 | 79.1% | CN¥1.38 Billion | CN¥1.38 Billion | CN¥- | CN¥1.74 Billion | ▲ +47.6 pp |
| 2020 | 31.6% | CN¥452.50 Million | CN¥452.50 Million | CN¥- | CN¥1.43 Billion | ▲ +13.0 pp |
| 2019 | 18.6% | CN¥244.69 Million | CN¥244.69 Million | CN¥- | CN¥1.31 Billion | ▼ -10.0 pp |
| 2018 | 28.7% | CN¥221.59 Million | CN¥221.59 Million | CN¥- | CN¥772.85 Million | ▼ -5.2 pp |
| 2017 | 33.9% | CN¥151.20 Million | CN¥151.20 Million | CN¥- | CN¥446.02 Million | ▼ -26.8 pp |
| 2016 | 60.7% | CN¥133.59 Million | CN¥133.59 Million | CN¥- | CN¥220.15 Million | — |